Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Nutr Food Res ; 65(10): e2001224, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33754444

RESUMEN

Occurrence of obesity and its associated metabolic disorders continues to escalate. The present study evaluates the anti-obesity effects of ethanolic fruit extract of Terminalia chebula (EETC) on high fat diet induced obese mice. The bioactive compounds present in the EETC is evaluated by Fourier-transform infrared (FT-IR), Gas chromatography-mass spectrometry (GC-MS), and Liquid chromatography-mass spectrometry (LC-MS) analysis. The effects of EETC on energy intake, glucose tolerance, and various biochemical parameters were analyzed using laboratory mice. Relative gene expression of Fatty acid synthase (FAS), Peroxisome proliferator-activated receptors α (PPARα), Carnitine palmitoyltransferase-1 (CPT-1), Tumor necrosis factor alpha (TNF-α) as well as Interleukin 6 (IL-6) were analyzed in liver and adipose tissues. The findings reveal the hypolipidemic and anti-obesity potential of EETC on high fat fed obese mice. EETC exerts its anti-obesity effects by suppressing lipogenesis through reduction in lipogenic enzyme (FAS) expression, increased fatty acid oxidation via PPARα and CPT-1 and by triggering the anti-inflammatory responses. To our knowledge, this is the first report of the effect of EETC on PPARα and CPT-1 in in vivo.


Asunto(s)
Fármacos Antiobesidad , Frutas/química , Obesidad/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Terminalia , Tejido Adiposo/metabolismo , Animales , Antiinflamatorios , Carnitina O-Palmitoiltransferasa/genética , Dieta Alta en Grasa , Ingestión de Energía/efectos de los fármacos , Ácido Graso Sintasas/antagonistas & inhibidores , Ácido Graso Sintasas/genética , Expresión Génica/efectos de los fármacos , Lipogénesis/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Obesidad/etiología , PPAR alfa/genética
2.
Artículo en Inglés | MEDLINE | ID: mdl-32071059

RESUMEN

We report a systematic, cellular phenotype-based antimalarial screening of the Medicines for Malaria Venture Pathogen Box collection, which facilitated the identification of specific blockers of late-stage intraerythrocytic development of Plasmodium falciparum First, from standard growth inhibition assays, we identified 173 molecules with antimalarial activity (50% effective concentration [EC50] ≤ 10 µM), which included 62 additional molecules over previously known antimalarial candidates from the Pathogen Box. We identified 90 molecules with EC50 of ≤1 µM, which had significant effect on the ring-trophozoite transition, while 9 molecules inhibited the trophozoite-schizont transition and 21 molecules inhibited the schizont-ring transition (with ≥50% parasites failing to proceed to the next stage) at 1 µM. We therefore rescreened all 173 molecules and validated hits in microscopy to prioritize 12 hits as selective blockers of the schizont-ring transition. Seven of these molecules inhibited the calcium ionophore-induced egress of Toxoplasma gondii, a related apicomplexan parasite, suggesting that the inhibitors may be acting via a conserved mechanism which could be further exploited for target identification studies. We demonstrate that two molecules, MMV020670 and MMV026356, identified as schizont inhibitors in our screens, induce the fragmentation of DNA in merozoites, thereby impairing their ability to egress and invade. Further mechanistic studies would facilitate the therapeutic exploitation of these molecules as broadly active inhibitors targeting late-stage development and egress of apicomplexan parasites relevant to human health.


Asunto(s)
Antimaláricos/farmacología , Evaluación Preclínica de Medicamentos/métodos , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/crecimiento & desarrollo , Fragmentación del ADN/efectos de los fármacos , Humanos , Merozoítos/efectos de los fármacos , Pruebas de Sensibilidad Parasitaria , Esquizontes/efectos de los fármacos , Trofozoítos/efectos de los fármacos
3.
Sci Rep ; 8(1): 14974, 2018 10 08.
Artículo en Inglés | MEDLINE | ID: mdl-30297791

RESUMEN

Antimalarial drug discovery expands on targeted and phenotype-based screening of potential inhibitory molecules to ascertain overall efficacy, phenotypic characteristics and toxicity, prior to exploring pharmacological optimizations. Candidate inhibitors may have varying chemical properties, thereby requiring specific reconstitution conditions to ensure solubility, stability or bioavailability. Hence, a variety of solvents, buffers, detergents and stabilizers become part of antimalarial efficacy assays, all of which, above certain threshold could interfere with parasite viability, invasion or red blood cell properties leading to misinterpretation of the results. Despite their routine use across malaria research laboratories, there is no documentation on non-toxic range for common constituents including DMSO, glycerol, ethanol and methanol. We herein constructed a compatibility reference guide for 14 such chemicals and estimated their Permissible Limit against P. falciparum asexual stages at which viability and replication of parasites are not compromised. We also demonstrate that at the estimated Permissible Limit, red blood cells remain healthy and viable for infection by merozoites. Taken together, this dataset provides a valuable reference tool for the acceptable concentration range for common chemicals during in vitro antimalarial tests.


Asunto(s)
Antimaláricos/toxicidad , Detergentes/toxicidad , Descubrimiento de Drogas/métodos , Eritrocitos/efectos de los fármacos , Excipientes/toxicidad , Plasmodium falciparum/efectos de los fármacos , Solventes/toxicidad , Antimaláricos/química , Antimaláricos/farmacología , Tampones (Química) , Detergentes/química , Evaluación Preclínica de Medicamentos , Eritrocitos/parasitología , Excipientes/química , Humanos , Malaria/tratamiento farmacológico , Solventes/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA